首页 uniQure NV(usQURE)-基本信息

uniQure NV(usQURE)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:35.27

最高价:35.49

成交量:201799.0

昨收价:35.47

最低价:33.92

最新价:34.07

行情图标
概要信息

英文名称:uniQure NV


简介:uniQure N.V.作为私人有限责任公司于2012年1月9日依照荷兰相关法律条文成立


电话:31-20-2406000,31-20-5667394


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

uniQure N.V.是一家生物制药公司,通过其技术平台,开发以腺相关病毒(AAV)为基础之基因疗法,用于多方面治疗领域。 uniQure公司的上市产品Glybera——是一种已被批准用于治疗脂蛋白脂解酵素缺乏症患者的基因治疗产品。 此外,uniQure还开发AMT-060,是一种基因疗法,产品已完成治疗B型血友病之I/II期临床试验。 S100A1,是一项临床前候选药物,用于治疗郁血性心衰竭。 AMT-021基因疗法,已完成急性间断性紫质症的I临期床试验。 AMT-110基因疗法,处B型圣菲利柏氏症的I/II期临床试验阶段。 AAV2/神经胶细胞递送神经滋养因子( GDNF),用于帕金森氏症。 AMT-130,用于治疗亨丁顿氏舞蹈症。uniQure N.V.与Chiesi Farmaceutici S.p.A.、Digna Biotech、Institut Pasteur、加州大学旧金山分校、Bristol-Myers Squibb及4D Molecular Therapeutics参与共同研究。

交易日期 交易人 职位 类型 交易份额 价格
2017-06-28 Petry (Harald) Officer Sell 21547 6.02
2017-06-28 Petry (Harald) Officer Buy 21547 3.50
2017-06-27 Petry (Harald) Officer Buy 27753 3.49
2017-06-27 Petry (Harald) Officer Sell 27753 6.01
2017-06-26 Petry (Harald) Officer Sell 7700 6.00
2017-06-26 Petry (Harald) Officer Buy 7700 3.48
2017-06-25 Petry (Harald) Officer Buy 58075 3.43
2017-06-25 Petry (Harald) Officer Sell 58075 6.01
2017-06-21 Petry (Harald) Officer Buy 155 3.42
2017-06-21 Petry (Harald) Officer Sell 155 6.00
2017-06-04 Zelenkofske (Steven L) Officer Buy 175000 --
2017-03-20 Petry (Harald) Officer Sell 25422 6.03
2017-03-20 Petry (Harald) Officer Buy 25422 3.30

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Franklin Advisers, Inc. 556000 1.47% 345100 163.63% 2019-03-31
Redmile Group, LLC 1307522 3.46% 4100 0.31% 2019-03-31
Invesco Ltd (OFI / OppenheimerFunds) 1428856 3.77% -5303 -0.37% 2019-07-31
Nantahala Capital Management, LLC 1518690 4.02% -959977 -38.73% 2019-03-31
OppenheimerFunds Inc 1817534 4.81% 90391 5.23% 2019-03-31
Fidelity Management & Research Company 1913646 5.06% -99886 -4.96% 2019-07-31
Consonance Capital Management LP 1985460 5.26% 89234 4.71% 2019-03-31
FMR Inc 3688791 9.77% 29629 0.81% 2019-03-31
Fidelity Management and Research Company 3688791 9.77% 29629 0.81% 2019-03-31
Federated Investors Inc 1272228 3.37% -293372 -18.74% 2019-03-31
Federated Equity Mgmt Co. Of Penn 1235400 3.26% -330200 -21.09% 2019-07-31
Fidelity SelectCo, LLC 973352 2.57% -223048 -18.64% 2019-07-31
Franklin Resources Inc 556000 1.47% 345100 163.63% 2019-03-31
Baker Bros Advisors LP 605000 1.60% -- -- 2019-03-31
Lord, Abbett & Co LLC 647626 1.71% 496355 328.12% 2019-03-31
Macquarie Group Ltd 680000 1.80% 83000 13.90% 2019-03-31
Delaware Management Company 693000 1.83% -- -- 2019-07-31
Fidelity Management Trust Co 731530 1.93% -- -- 2019-07-31
683 Capital Management LLC 750000 1.99% -335000 -30.88% 2019-03-31
Boxer Capital LLC 950000 2.52% -250000 -20.83% 2019-03-31
Eventide Asset Management, LLC 538700 1.43% -197509 -26.83% 2019-03-31
Millennium Management LLC 767098 2.03% 283373 58.58% 2018-12-31
OFI Global Asset Management, Inc. 1332390 3.52% 6045 0.46% 2019-04-30
BlackRock Inc 468249 1.24% -12857 -2.67% 2018-12-31
Forbion I Co II Management B V 1865494 4.96% -- -- 2017-12-31
Fidelity International Ltd 832012 2.21% -73011 -8.07% 2018-09-30
Perceptive Advisors LLC 972831 2.61% -471797 -32.66% 2018-09-30
Delaware Management Business Trust 597000 1.60% -- -- 2018-09-30
Federated Global Inv Mgmt Corp 1565600 4.20% 474320 43.46% 2018-09-30
Morgan Stanley & Co Inc 670062 1.80% -54808 -7.56% 2018-06-30
Morgan Stanley - Brokerage Accounts 701259 1.88% -44160 -5.92% 2018-06-30
ForUniQure B.V. 4376883 13.78% 4376883 -- 2018-04-23
Coller Investment Management Ltd 2118520 6.88% 99009 4.90% 2017-12-14
Adage Capital Partners Gp LLC 348482 0.94% 150000 75.57% 2018-06-30
Parallax Volatility Advisers, LLC 256269 0.69% 256269 -- 2018-06-30
Franklin Advisers Inc 243500 0.66% 243500 -- 2018-06-30
Susquehanna Financial Group, LLLP 235829 0.64% -27221 -10.35% 2018-06-30
Invesco PowerShares Capital Mgmt LLC 176129 0.65% 580 0.33% 2018-08-30
Citadel Advisors Llc 300685 0.95% 279468 1317.19% 2018-03-31
Fidelity Institutional Asset Management 891000 2.80% -44400 -4.75% 2018-03-31
Jackson National Asset Management LLC 191348 0.52% 191348 -- 2018-06-30
Tekla Capital Management LLC 199750 0.63% -133100 -39.99% 2018-03-31
Point72 Asset Management, L.P. 225000 0.72% 225000 -- 2017-12-31
Susquehanna International Group, LLP 263050 0.83% -27082 -9.33% 2018-03-31
Foresite Capital Management II LLC 109350 0.35% 109350 -- 2017-12-31
Royce & Associates, LLC 125000 0.40% 125000 -- 2017-12-31
PDT Partners, LLC 135100 0.43% -3965 -2.85% 2018-03-31
Bogle Investment Management L P 181378 0.58% 181378 -- 2017-12-31
Two Sigma Investments LLC 138891 0.44% 138891 -- 2017-12-31
D. E. Shaw & Co LP 106442 0.34% 106442 -- 2017-12-31
Gilde Healthcare Holding BV 1056946 4.18% -215943 -16.96% 2016-12-31
Forbion I Management BV 1530501 6.06% -- -- 2016-12-31
BlackRock Fund Advisors 429989 1.23% -1356 -0.31% 2018-03-21
SELECTRA MANAGEMENT COMPANY S.A. 69509 0.23% -64493 -48.13% 2018-02-28
P.a.w. Capital Corp 80000 0.26% -25000 -23.81% 2017-12-31
Deutsche Bank AG 169056 0.66% 18282 12.13% 2017-09-30
Renaissance Technologies Corp 306700 1.20% -41400 -11.89% 2017-09-30
Dafna Capital Management LLC 175307 0.68% -28600 -14.03% 2017-09-30
Spark Investment Management LLC 161600 0.63% -98500 -37.87% 2017-09-30
Columbia Mangmt Investment Advisers, LLC 68485 0.22% -- -- 2017-12-31
Mangrove Partners 106634 0.42% 66763 167.45% 2017-09-30
Merrill Lynch & Co Inc 98176 0.38% -66400 -40.35% 2017-09-30
J.P. Morgan Securities Inc 57563 0.22% -918 -1.57% 2017-09-30
Cooperatieve AAC LS U.A. 987674 4.06% -- -- 2015-12-31
Orbimed Advisors, LLC 489000 1.95% 293600 150.26% 2016-09-30
Close Finsbury Asset Management Limited 489000 1.95% -- -- 2016-10-31
Putnam Investment Management,LLC 340849 1.36% -33382 -8.92% 2016-09-30
UBS Asset Mgmt Americas Inc 327809 1.30% -4400 -1.32% 2016-09-30
UBS Group AG 326600 1.30% -- -- 2016-10-31
Robeco Investment Management, Inc. 233262 0.93% 233262 -- 2016-12-31
Chiesi FarmaceuticiS.p.A. 1109214 3.00% 26976084 0.10% 1999-11-30
Cooperatieve Gilde Healthcare II U.A. 1740315 3.00% 42324461 0.10% 1999-11-30
FMR, LLC 1759490 3.00% 42790797 0.10% 1999-11-30
Coller International Partners V-A,L.P. 2019511 3.00% 49114508 0.10% 1999-11-30
Sander Slootweg 4393524 3.00% 106850504 0.20% 1999-11-30
Sander van Deventer 4402956 3.00% 107079890 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Invesco Oppenheimer VI Global Fund 204850 0.54% -3590 -1.72% 2019-06-30
Invesco Oppenheimer Global Fund 927330 2.45% -- -- 2019-06-30
Federated Kaufmann Fund 800000 2.11% -400000 -33.33% 2019-03-31
Delaware Healthcare Fund 693000 1.83% -- -- 2019-06-30
Fidelity Growth Company Commingled Pool 687430 1.82% -- -- 2019-06-30
Fidelity Special Situations Fund 419392 1.11% -- -- 2019-03-31
Federated Kaufmann Small Cap Fund 414000 1.09% 81000 24.32% 2019-03-31
iShares Nasdaq Biotechnology ETF 373139 0.99% 3877 1.05% 2019-07-30
Lord Abbett Developing Growth Fund 371399 0.98% 2069 0.56% 2019-05-31
Franklin Biotechnology Discovery Fund 206000 0.54% -- -- 2019-06-30
Fidelity Advisor 220000 0.58% -30000 -12.00% 2019-06-30
Fidelity 252700 0.67% -- -- 2019-06-30
T. Rowe Price QM US Small-Cap Gr Eq Fd 253100 0.67% 36600 16.91% 2019-06-30
Eventide Healthcare & Life Sciences Fund 260000 0.69% -197509 -43.17% 2019-03-31
Eventide Gilead Fund 278700 0.74% -- -- 2019-03-31
Fidelity Global Innovators Cl 214894 0.57% 408 0.19% 2018-09-30
HBM Healthcare Investments AG 250000 0.66% 250000 -- 2018-12-31
Oppenheimer Global Fund 853620 2.26% -- -- 2019-03-31
Oppenheimer Global Fund/VA 182420 0.48% -- -- 2019-02-28
JNL/Oppenheimer Global Growth Fund 175800 0.47% -5600 -3.09% 2018-12-31
LSP Life Sciences Fund N.V. 158339 0.42% 39539 33.28% 2019-01-31
Fidelity Special Situations Class 576394 1.55% -- -- 2018-09-30
Oppenheimer Main Street All Cap Fund 110780 0.30% -- -- 2018-10-31
Lupus alpha Fds Lupus alpha Micro Champ 159900 0.43% 99900 166.50% 2017-12-31
Eventide Gilead N 278700 0.75% 278700 -- 2018-06-30
iShares Nasdaq Biotechnology 410690 1.09% -783 -0.19% 2018-09-12
Eventide Healthcare & Life Sciences A 475350 1.28% 140350 41.90% 2018-06-30
Delaware Healthcare A 597000 1.61% -- -- 2018-07-31
Oppenheimer Global A 727890 1.96% 5910 0.82% 2018-07-31
Federated Kaufmann R 852471 2.30% 149536 21.27% 2018-06-30
Federated Kaufmann Small Cap A 216760 0.58% 19840 10.08% 2018-06-30
Oppenheimer Global VA Svc 169110 0.46% -560 -0.33% 2018-07-31
JNL/Oppenheimer Global Growth B 174730 0.47% 174730 -- 2018-06-30
PowerShares DWA Healthcare Momentum ETF 100553 0.26% -- -- 2018-09-13
VY Oppenheimer Global I 108100 0.29% 108100 -- 2018-06-30
Royce Smaller-Companies Growth Svc 100000 0.27% -25000 -20.00% 2018-06-30
PowerShares DWA SmallCap Momentum ETF 90429 0.24% -- -- 2018-09-13
Oppenheimer Main Street Select A 110780 0.30% -- -- 2018-07-31
Met Invt Ser Oppenheimer Glbl Eq B 90510 0.24% 90510 -- 2018-06-30
Oppenheimer Main Street Small Cap VA Svc 94020 0.25% -- -- 2018-06-30
Franklin Biotechnology Discovery A 84700 0.23% -- -- 2018-06-30
Columbia VP US Equities 2 69150 0.19% 18050 35.32% 2018-06-30
Fidelity VIP Health Care Inv 71206 0.19% 6085 9.34% 2018-05-31
Oppenheimer Main Street Small Cap A 52258 0.14% 52258 -- 2018-05-31
Strategic Advisers 60000 0.19% -- -- 2018-04-30
Tekla Life Sciences Investors 75482 0.24% 2853 3.93% 2018-03-31
Vanguard Health Care ETF 50769 0.14% 2846 5.94% 2018-05-31
iShares Micro-Cap 60071 0.18% -- -- 2018-06-21
BioShares 43456 0.12% -- -- 2018-06-14
Columbia Small Cap Growth I Z 47700 0.15% -- -- 2018-03-31
Bogle Small Cap Growth Instl 45921 0.15% -16637 -26.59% 2018-02-28
RS Technology A 35040 0.11% 35040 -- 2017-12-31
Fidelity Asset Manager 24862 0.08% 24862 -- 2017-12-31
AXA/Lord Abbett Micro Cap K 3056 0.01% -- -- 2017-10-31
Putnam Global Health Care A 258886 1.03% -7797 -2.92% 2016-12-31
Boston Partners Long/Short Equity Instl 233262 0.93% 233262 -- 2016-12-31
TFS Market Neutral 35216 0.14% 1465 4.34% 2016-10-31
Putnam VT Global Health Care IA 26675 0.11% -803 -2.92% 2016-12-31
Putnam Small Cap Growth A 15124 0.06% 200 1.34% 2016-12-31
Putnam Capital Opportunities A 17576 0.07% -5100 -22.49% 2016-12-31
Voya Multi-Manager International Sm Cp A 10205 0.04% 10205 -- 2016-12-31
Great-West Multi-Manager Sm Cp Gr Instl 2271 0.01% -- -- 2016-11-30
Putnam VT Capital Opportunities IB 1785 0.01% -- -- 2016-12-31
Weiss Alternative Balanced Risk I 18 -- 3 20.00% 2016-12-31
Fidelity Advisor® Biotechnology Fund 158829 0.70% -- -- 2015-09-30
Putnam Global Health Care Fund 266683 1.20% -- -- 2015-09-30
Fidelity® Blue Chip Growth Fund 303687 1.30% -- -- 2015-09-30
Fidelity® OTC Portfolio 304700 1.30% -- -- 2015-09-30
UBS (Lux) EF Biotech (USD) 326600 1.40% -- -- 2015-07-31
Oppenheimer International Small Co Fund 158720 0.70% -- -- 2015-09-30
Fidelity® Series Blue Chip Growth Fund 146459 0.60% -- -- 2015-09-30
Candriam Eqs L Biotechnology 97400 0.40% 7400 8.20% 2015-09-30
Pyramis Small Capitalization Core Collective Investment Trust 90700 0.50% 90700 -- 2014-12-31
Fidelity® Ser Opportunistic Insights Fd 54800 0.20% -- -- 2015-09-30
DWS Biotech 40000 0.20% -- -- 2015-09-30
Tocqueville Opportunity 35500 0.20% 3500 10.90% 2015-09-30
Dreyfus Select Managers Small Cap Gr Fd 29661 0.10% -- -- 2015-09-30
Fidelity® Select Biotechnology Portfolio 870789 3.80% -- -- 2015-09-30

Philip Astley-Sparke Philip Astley-Sparke is a businessperson who founded Replimune Group, Inc. and who has been at the helm of 6 different companies. Presently, he is Chairman of Oxyrane UK Ltd., Chairman of uniQure NV, Executive Chairman, Secretary & Treasurer at Replimune Group, Inc. and Venture Partner at Forbion Capital Partners Management Holding BV. In his past career he occupied the position of Vice President & General Manager at Amgen, Inc. President & Chief Executive Officer for BioVex, Inc. and President & Chief Executive Officer of BioVex Group, Inc. (both are subsidiaries of Amgen, Inc.) and President at uniQure, Inc. Philip Astley-Sparke received an undergraduate degree from the University of Bristol.
Sander J. van Deventer Sander J. van Deventer is an entrepreneur who founded uniQure NV, Amsterdam Molecular Therapeutics (AMT) Holding NV and Dezima Pharma BV. Presently, he occupies the position of Chief Scientific Officer & GM-Amsterdam at uniQure NV. He is also Professor at Leids Universitair Medisch Centrum and on the board of 5 other companies. In his past career he was Managing Partner at Forbion Capital Partners Management Holding BV, Professor at Academic Medical Center, Director at Amsterdam Molecular Therapeutics (AMT) Holding NV, Chief Executive Officer at Dezima Pharma BV and Professor-Experimental Medicine at the University of Amsterdam. Sander J. van Deventer received a doctorate and an undergraduate degree from the University of Amsterdam.
Jack L. Kaye Founder of Westhouse Medical Services Plc and Thorn Medical Plc, Jack L. Kaye is on the board of uniQure NV and Thorn Medical Plc (former Chief Executive Officer & Director). In the past he occupied the position of Chief Executive Officer at Westhouse Medical Services Plc, Chief Executive Officer & Director at Technis International Plc and Partner at Deloitte LLP (New York). He received an undergraduate degree from Baruch College.
Jack L. Kaye Jack L. Kaye founded Westhouse Medical Services Plc and Thorn Medical Plc. Mr. Kaye is on the board of uniQure NV and Thorn Medical Plc (former Chief Executive Officer & Director). He previously held the position of Chief Executive Officer for Westhouse Medical Services Plc, Chief Executive Officer & Director at Technis International Plc and Partner at Deloitte LLP (New York). Jack L. Kaye received an undergraduate degree from Baruch College.
Maria E. Cantor Presently, Maria E. Cantor is Senior VP-Investor Relations & Communications at uniQure NV. Ms. Cantor previously was Director-Public Relations & Marketing at St. Elizabeth's Medical Center, SVP-Corporate Affairs & Head-Investor Relations at ARIAD Pharmaceuticals, Inc., Director-Marketing & Communications at SunLink ScriptsRx LLC and Senior Director-Corporate Communications at Genzyme Corp. She received a graduate degree from Syracuse University and an undergraduate degree from Emerson College.
Steven L. Zelenkofske Presently, Steven L. Zelenkofske is Chief Medical Officer of uniQure NV and Chief Medical Officer & Executive Vice President at Achillion Pharmaceuticals, Inc. He is also Associate Professor at Hershey Medical Center and Associate Professor at Philadelphia College of Osteopathic Medicine. Dr. Zelenkofske previously occupied the position of Clinical Director at The Heart Care Group, Chief Medical Officer of Regado Biosciences, Inc., VP-Cardiovascular & Thrombosis Medical Unit at Sanofi-Aventis Pharmaceuticals and Chief Patient Safety Officer at Cardiac Rhythm Management. Dr. Zelenkofske received a graduate degree and an undergraduate degree from Emory University and a doctorate from Philadelphia College of Osteopathic Medicine.
David J. Cerveny David J. Cerveny is Secretary, Chief Legal Officer & General Counsel at uniQure NV. In the past Mr. Cerveny held the position of Associate at Proskauer Rose LLP, Secretary, Chief Legal Officer & General Counsel at ConforMIS, Inc., Chief Intellectual Property Counsel at Palomar Medical Technologies LLC, Partner at Hale & Dorr LLP and Electronics Engineer at McDonnell Douglas Corp. Mr. Cerveny received an undergraduate degree from Marquette University and a graduate degree from Boston College Law School.
Jeremy P. Springhorn Jeremy P. Springhorn is on the board of uniQure NV and Mythic Therapeutics, Inc. and Member-Overseers Board at Colby College, Member of Licensing Executives Society, Director-Fundraising & Development at Juvenile Diabetes Research Foundation Canada, Chief Business Officer at Syros Pharmaceuticals, Inc. and Member-Licensing Executives Society at Biotechnology Innovation Organization. In the past Jeremy P. Springhorn occupied the position of Partner & Head- Corporate Development at Flagship Pioneering, Scientific Advisor at Arradial, Inc. and VP-Corporate Strategy & Business Development at Alexion Pharmaceuticals, Inc. Dr. Springhorn received a doctorate from Louisiana State University and an undergraduate degree from Colby College.
Matthew C. Kapusta Presently, Matthew C. Kapusta holds the position of CEO, Chief Financial Officer & Executive Director at uniQure NV. He previously occupied the position of Senior Vice President-Business Development of AngioDynamics, Inc., Vice President-Finance & Strategic Planning at Smith & Nephew Plc and Vice President-Finance of Smith & Nephew Orthopaedics Ltd. (a subsidiary of Smith & Nephew Plc) and MD-Healthcare Investment Banking at Collins Stewart, Inc. Mr. Kapusta received an MBA from The Leonard N Stern School of Business and an undergraduate degree from Stephen M. Ross School of Business.
Alexander E. Kuta Alexander E. Kuta holds the position of Senior Vice President-Regulatory Affairs at uniQure NV. In the past Dr. Kuta was Principal at AMAG Pharmaceuticals, Inc., Principal at US Food & Drug Administration, Principal at Genzyme Corp., Vice President & Head-Regulatory Affairs at EMD Serono, Inc. and Vice President-Global Regulatory Affairs at Lantheus Medical Imaging, Inc. Dr. Kuta received an undergraduate degree from St. John's University and a doctorate from Chicago Medical School.
David D. Meek David D. Meek is a businessperson who has been at the helm of 6 different companies and currently holds the position of Chairman at Entasis Therapeutics Holdings, Inc., Chairman for Entasis Therapeutics, Inc. (a subsidiary of Entasis Therapeutics Holdings, Inc.) and Chief Executive Officer & Director at Ipsen SA, Chairman for Ipsen Pharma SAS (a subsidiary of Ipsen SA). Mr. Meek is also on the board of Pharmaceutical Research & Manufacturers of America, European Federation of Pharmaceutical Industries & Assns and uniQure NV. In his past career he occupied the position of President & Chief Executive Officer for Novartis Pharmaceuticals Canada, Inc., Chief Executive Officer of Ipsen Manufacturing Ireland Ltd., Chief Commercial Officer of Endocyte, Inc. and Executive Vice President & President-Oncology at Baxalta, Inc. Mr. Meek received an undergraduate degree from the University of Cincinnati (Ohio).
Madhavan Balachandran Madhavan Balachandran is on the board of Stevanato Group SpA, uniQure NV, Catalent, Inc. and Fortuna Fix, Inc. In his past career Mr. Balachandran occupied the position of Senior Vice President-Manufacturing at Amgen, Inc., Vice President-Engineering of Glaxo Wellcome, Inc., Principal at Battelle Memorial Institute and Vice President of Puerto Rico USA Citizenship Foundation. Mr. Balachandran received an MBA from East Carolina University, an undergraduate degree from Indian Institute of Technology Bombay and a graduate degree from State University of New York at Buffalo.
Paula Soteropoulos Currently, Paula Soteropoulos holds the position of Chief Executive Officer & Director at Akcea Therapeutics, Inc. Ms. Soteropoulos is also on the board of uniQure NV and JFYNetworks, Inc. She previously occupied the position of Senior Vice President-Strategic Alliances at Moderna, Inc. and Vice President & GM-Global Cardiovascular Business at Genzyme Corp. Paula Soteropoulos received a graduate degree and an undergraduate degree from Tufts University.
Jonathan Garen Mr. Jonathan Garen is a Chief Business Officer at uniQure NV. Mr. Garen was previously employed as a Chief Business Officer by Syros Pharmaceuticals, Inc., an Assistant Vice President-Business Development by Tango Merger Sub 2 LLC, a Director-Global Licensing by Pharmacia Corp., and a Vice President by Technology Exchange, Inc. He received his undergraduate degree from Massachusetts Institute of Technology and a graduate degree from Yale University.
Scott T. McMillan Presently, Scott T. McMillan holds the position of Chief Operating Officer at uniQure NV. In the past he occupied the position of Senior VP-Quality & Technical Operations at AMAG Pharmaceuticals, Inc., SVP-Quality & Technical Operations at Johnson Matthey Pharmaceutical Materials, Inc. and SVP-Quality & Technical Operations at AVANT Immunotherapeutics, Inc. Dr. McMillan received an undergraduate degree from the University of Delaware and a doctorate from Georgia Institute of Technology.
David Schaffer Dr. David Schaffer is a Co-Chairman & Chief Scientific Officer at 4d Molecular Therapeutics, Inc. and a Professor at University of California, Berkeley. He is on the Board of Directors at uniQure NV and The Berkley Stem Cell Center. Dr. Schaffer was previously employed as an Associate Professor by University of California. He also served on the board at American Society of Gene Therapy and Society for Biological Engineering. He received his undergraduate degree from Stanford University and a doctorate degree from Massachusetts Institute of Technology.
Jonathan Garen Founder of Technology Exchange, Inc., Jonathan Garen is Chief Business Officer for uniQure NV. In the past he occupied the position of Assistant Vice President-Business Development at Allergan Plc and Assistant Vice President-Business Development at Forest Laboratories LLC (a subsidiary of Allergan Plc), Chief Business Officer of Syros Pharmaceuticals, Inc., Vice President for Technology Exchange, Inc. and Director-Global Licensing at Pharmacia Corp. Jonathan Garen received a graduate degree from Yale University and an undergraduate degree from Massachusetts Institute of Technology.
Eva M. Mulder Currently, Eva M. Mulder is Manager-Investor Relations & Communications at uniQure NV.
Eva M. Mulder Currently, Eva M. Mulder is Manager-Investor Relations & Communications at uniQure NV.
Kathy Bodley Presently, Kathy Bodley is Director-Human Resources for uniQure NV.
Christian Klemt Presently, Christian Klemt holds the position of Chief Accounting Officer of uniQure NV. In his past career Mr. Klemt was Regional Finance Director & Country Manager at CGG and Group Finance Manager at LyondellBasell Industries NV. Mr. Klemt received an MBA from the University of M�0�1�0�4nster.
Robert Gut Presently, Robert Gut is Executive Director & Chief Medical Officer at uniQure NV. In the past Dr. Gut was Vice President-Medical Affairs & Development at Radius Health, Inc., VP-Clinical Development & Medical Affairs at Novo Nordisk, Inc. and Chief Medical Officer, Head-Clinical & Medical at Versartis, Inc. Dr. Gut received a doctorate from Medical University of Lublin.
David J. Cerveny David J. Cerveny is Secretary, Chief Legal Officer & General Counsel at uniQure NV. In the past Mr. Cerveny held the position of Associate at Proskauer Rose LLP, Secretary, Chief Legal Officer & General Counsel at ConforMIS, Inc., Chief Intellectual Property Counsel at Palomar Medical Technologies LLC, Partner at Hale & Dorr LLP and Electronics Engineer at McDonnell Douglas Corp. Mr. Cerveny received an undergraduate degree from Marquette University and a graduate degree from Boston College Law School.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐